Almirall launches Skilarence in Europe

On Sept. 14, Almirall S.A. (Madrid:ALM) launched Skilarence in Europe to treat moderate to severe chronic plaque psoriasis. Skilarence is an oral dimethyl fumarate targeting nuclear factor (erythroid...